SpecialtiesQuestion

Do you use different follow-up intensity and discontinuation criteria for mixed-pattern (R 2–5) versus cholestatic-pattern (R <2) DILI?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In suspected antibiotic-associated cholestatic DILI with jaundice and no obstructing lesion on MRCP, what specific clinical or laboratory trajectory triggers you to proceed to early liver biopsy to evaluate for evolving vanishing bile duct syndrome rather than continued close outpatient monitoring?

For checkpoint inhibitor–associated cholangitis/secondary sclerosing cholangitis, what is your clinically actionable corticosteroid-trial algorithm (including which imaging, histologic, and biochemical response features define steroid responsiveness vs futility)?

What patient features, serologic, imaging, clinical, or otherwise, would make you order targeted cholestasis-gene sequencing (e.g., ABCB11/ABCB4/ATP8B1) in severe or prolonged cholestatic DILI because the result would meaningfully change management?

With pan-genotypic treatment options available, when do you consider checking the genotype in patients with Hepatitis C?

If a patient meets stopping criteria but is on tenofovir-based therapy, would you ever switch to entecavir before planned cessation to potentially reduce post-withdrawal flare risk, and what evidence threshold would make that strategy clinically actionable for you?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.